MétaCan
Menu
← Back to cohort

4-Year Follow-up of Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Magnetic Resonance Imaging (MRI) Outcomes From DEFINE, CONFIRM, and the ENDORSE Extension Study (P3.160)

2014· article· en· W2300125208 on OpenAlexaff
Douglas L. Arnold, Robert J. Fox, Ralf Gold, Eva Havrdová, Ludwig Kappos, Tarek Yousry, Ray Zhang, Minhua Yang, Vissia Viglietta, Sarah Sheikh, David Miller

Bibliographic record

VenueNeurology · 2014
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsMontreal Neurological Institute and Hospital
Fundersnot available
KeywordsRelapsing remittingMultiple sclerosisDimethyl fumarateMagnetic resonance imagingMedicineRadiologyImmunology

Abstract

fetched live from OpenAlex

OBJECTIVE: Report 4-year interim MRI outcomes with delayed-release dimethyl fumarate (DMF) from DEFINE/CONFIRM and ENDORSE. BACKGROUND: Delayed-release DMF demonstrated efficacy and safety in RRMS patients in the 2-year, Phase 3 DEFINE/CONFIRM studies. ENDORSE is an ongoing, 5-year, dose-blind extension study of DEFINE/CONFIRM evaluating long-term safety and efficacy. DESIGN/METHODS: In ENDORSE, patients randomized in DEFINE/CONFIRM to delayed-release DMF 240 mg twice- (BID) or three-times daily (TID) continued on the same dosage. Patients randomized to placebo (PBO) or glatiramer acetate (GA) were re-randomized 1:1 to delayed-release DMF BID or TID. Brain scans were obtained yearly in the ENDORSE MRI cohort. Efficacy was analyzed (June 12, 2013 cutoff) by parent/extension study arm: BID/BID, TID/TID, PBO/BID, PBO/TID, GA/BID, GA/TID. RESULTS: 718 of the 982 MRI cohort patients who completed DEFINE/CONFIRM were dosed in ENDORSE (n=206 [BID/BID], 215 [TID/TID], 96 [PBO/BID], 93 [PBO/TID], 48 [GA/BID], 60 [GA/TID]). Among patients continuing delayed-release DMF treatment, during Year 1 and Year 2, respectively, in ENDORSE: 64% and 68% (BID/BID) and 60% and 61% (TID/TID) were free of new/enlarging T2 lesions; 72% and 76% (BID/BID) and 67% and 70% (TID/TID) were free of new T1-hypointense lesions; 89% and 88% (BID/BID) and 85% and 84% (TID/TID) were free of gadolinium-enhancing lesions at 1-year and 2-year assessments. For patients switching from PBO, no new/enlarging T2 lesions were observed in 31% and 33% (PBO/BID) and 18% and 31% (PBO/TID) during Year 1 and Year 2 on placebo in DEFINE/CONFIRM, and in 43% and 73% (PBO/BID) and 47% and 77% (PBO/TID) during Year 1 and Year 2 on delayed-release DMF in ENDORSE. CONCLUSIONS: Reduced frequency of new MRI lesions is maintained over 4 years among patients continuing therapy. Switching from placebo to delayed-release DMF, patients demonstrated MRI outcomes similar to those with delayed-release DMF in DEFINE/CONFIRM. Together with clinical efficacy and an acceptable safety profile, results support delayed-release DMF as a potential long-term treatment option for relapsing MS. Study Supported by: Biogen Idec

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.019

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0010.000
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.036
GPT teacher head0.274
Teacher spread0.238 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueNeurology→Same topicMultiple Sclerosis Research Studies→French-language works237,207→